Clinical and inflammatory characteristics of participants with and without Tropheryma sequences
| Tropheryma present | Tropheryma absent | p-value | |
| Subjects | 7 | 23 | |
| Age years | 53±14 | 60±9 | 0.175 |
| Male | 2 (29) | 10 (43) | 0.403 |
| Atopic | 5 (71) | 19 (87) | 0.347 |
| Ex-smoker | 4 (57) | 12 (52) | 0.581 |
| Smoking pack-years | 16.7 (7.7, 47.8) | 14.4 (1.3, 40.3) | 0.505 |
| FEV1 % predicted | 81±24 | 76±15 | 0.577 |
| FEV1/FVC % | 71±10 | 68±10 | 0.517 |
| ICS dose µg | 2000 (2000, 4000) | 2000 (1000, 2000) | 0.150 |
| ACQ6 score | 1.0±0.7 | 1.5±1.0 | 0.250 |
| VAS symptom scores | |||
| Breathlessness | 6.5 (2.1, 23.0) | 7.0 (4.1, 10.0) | 1.000 |
| Wheeze | 3.5 (1.0, 4.6) | 3.2 (0.8, 6.7) | 0.683 |
| Cough | 6.0 (3.7, 7.2) | 7.4 (2.2, 10.0) | 0.386 |
| Sputum production | 3.8 (0.0, 5.9) | 4.7 (1.8, 10.0) | 0.740 |
| Inflammatory cell counts | |||
| Total cell count ×106 mL–1 | 5.2 (3.3, 7.2) | 4.6 (2.2, 8.9) | 0.713 |
| Viability % | 85 (74, 94) | 81 (75, 84) | 0.328 |
| Neutrophils % | 40.9±25.5 | 41.8±25.7 | 0.942 |
| Eosinophils % | 1.8 (1.0, 7.0) | 1.5 (0.3, 4.0) | 0.769 |
| Macrophages % | 45 (35, 77) | 41 (21, 61) | 0.419 |
| Lymphocytes % | 1.0 (0.3, 2.5) | 0.5 (0.3, 1.0) | 0.457 |
| Columnar epithelial cells % | 0.5 (0.3, 2.5) | 1.3 (0.3, 3.0) | 0.475 |
| Squamous cells % | 6.8 (1.5, 9.5) | 3.6 (0.5, 6.3) | 0.154 |
Data are presented as n, mean±sd, n (%) or median (quartile 1, quartile 3), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6: Asthma Control Questionnaire 6; ICS: inhaled corticosteroid; VAS: visual analogue scale.